reviewed april 2026|next review october 2026|88 physicians psi has verified|658 published studies
Cerebrolysin
Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides and amino acids derived from porcine brain tissue, approved as a prescription neuroprotective treatment in over 60 countries for stroke recovery, traumatic brain injury, and dementia, but not approved by the FDA.
Evidence landscape: 658 published studies
658 published items. 52 human studies and 103 animal studies. The most extensively studied neurotrophic peptide preparation with clinical data across multiple neurological conditions.
- 52 Human
- 103 Animal
- 45 Reviews
- 458 Other research
Approved in over 60 countries for stroke recovery, traumatic brain injury (TBI), and dementia. Not FDA-approved in the United States.
The CASTA trial enrolled 1,070 acute stroke patients, making it one of the largest stroke recovery trials for any neurotrophic agent.
Contains low-molecular-weight peptides that engage TrkB and p75NTR receptors, replicating neurotrophic factor (BDNF/NGF) signaling. Not a single defined molecule.
PSI Assessment
Approved as a prescription neuroprotective treatment in over 60 countries, studied in the largest stroke recovery trial for any neurotrophic agent, and used in hospitals across Europe, Asia, and Latin America - yet never approved by the FDA. Cerebrolysin has the most extensive clinical track record of any neurotrophic peptide preparation. The CASTA trial enrolled 1,070 acute stroke patients. The evidence is strongest for acute stroke recovery, with consistent improvements in neurological outcomes across trials. The absence of FDA approval reflects differences in how regulatory agencies evaluate evidence, not safety or efficacy failure.
Approved in over 60 countries. The CASTA trial enrolled 1,070 acute stroke patients. Not FDA-approved.
The mechanism involves neurotrophic factor mimicry. Cerebrolysin contains low-molecular-weight peptides that engage TrkB and p75NTR receptors, activating PI3K/Akt and MAPK/ERK neuroprotective signaling pathways. This replicates the downstream effects of BDNF and NGF without being a single defined molecule. The mixture is standardized to contain consistent neurotrophic activity across batches. Administration is intravenous or intramuscular in clinical protocols.
What the evidence supports
Approved in over 60 countries for stroke recovery, TBI, and dementia. The CASTA trial (1,070 acute stroke patients) is one of the largest stroke recovery trials for any neurotrophic agent. Controlled trials in Alzheimer's disease show cognitive benefit on multiple assessment scales. Neurotrophic factor mimicry through TrkB and p75NTR receptor engagement is documented. 52 human studies provide the deepest clinical evidence base of any neurotrophic peptide preparation.
What is not yet established
Why the FDA has not approved Cerebrolysin despite extensive international clinical use. Whether the trial designs meet current Western regulatory standards for registration. Head-to-head comparison with approved stroke rehabilitation approaches. Long-term cognitive outcomes beyond trial durations.
Research Evidence
The findings below cover the CASTA stroke trial, the Alzheimer's clinical data, and the TBI recovery evidence.
Evidence by condition
Evidence dimensions across Cerebrolysin's investigated conditions. Acute stroke has the deepest evidence. TBI and Alzheimer's have supporting controlled trial data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Acute Stroke | ||||
| TBI | ||||
| Alzheimer's Disease | ||||
| Vascular Dementia | ||||
| Pediatric Neurodevelopmental |
The CASTA trial (1,070 acute stroke patients) showed improved neurological outcomes when Cerebrolysin was administered within 72 hours of acute ischemic stroke. Additional RCTs confirm benefits in early motor recovery and neurological function scores.
This is one of the largest stroke recovery trials for any neurotrophic agent. Some trials did not meet primary endpoints despite positive secondary outcomes.
Several clinical trials show improvement in ADAS-cog scores (a standard cognitive assessment) in mild-to-moderate Alzheimer's disease. A Cochrane review acknowledged the data but noted methodological limitations.
The Alzheimer's data is real but effect sizes are modest and methodological quality varies. It does not replace standard-of-care Alzheimer's treatments.
Controlled trials demonstrate improved cognitive outcomes in moderate-to-severe traumatic brain injury when Cerebrolysin is administered during the acute recovery phase.
TBI is heterogeneous and difficult to study. Sample sizes in TBI trials are smaller than stroke trials. Long-term follow-up data is limited.
52 Human|103 Animal|45 Reviews
View all 658 indexed studiesHow Cerebrolysin Works
Cerebrolysin is a complex biological mixture of low-molecular-weight neuropeptides (approximately 25% of the solution) and free amino acids (approximately 75%) derived from enzymatic breakdown of porcine brain proteins.
Cerebrolysin works like sending the brain a package of its own repair signals. The proteins in it mimic what the brain naturally uses to protect and rebuild neurons, particularly after damage from stroke or disease. It supports neuron survival and encourages the formation of new connections.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
The neuropeptide fraction contains fragments that activate TrkB and p75NTR receptors, mimicking BDNF and NGF signaling. Cerebrolysin modulates GSK-3B, reducing tau hyperphosphorylation in Alzheimer's disease models. It enhances synaptic density and long-term potentiation (LTP) in hippocampal circuits. The mixture also shows anti-apoptotic effects through upregulation of Bcl-2 and inhibition of caspase-3. The compositional complexity means the active components are not fully identified, making precise mechanistic attribution difficult.
What is Cerebrolysin being studied for?
Researchers are studying Cerebrolysin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Cerebrolysin overall. This means a compound can have human studies for one condition but only animal data for another.
Acute Stroke
·Human TrialsMultiple RCTs including the CASTA trial (1,070 patients) show Cerebrolysin improves neurological recovery when administered within 72 hours. Approved for this indication in over 60 countries.
Limitations: Some trials did not meet primary endpoints despite positive secondary outcomes. Current US stroke guidelines do not include Cerebrolysin.
TBI
·Human TrialsControlled trials show improved cognitive outcomes in moderate-to-severe TBI patients during the acute recovery phase.
Limitations: TBI is heterogeneous. Sample sizes are smaller than stroke trials. Long-term follow-up is limited.
Alzheimer's Disease
·Human TrialsSeveral clinical trials show improvement in ADAS-cog scores in mild-to-moderate Alzheimer's disease. Clinical response appears dose-dependent.
Limitations: Effect sizes are modest. Cochrane reviews call for larger, better-designed confirmatory trials.
Vascular Dementia
·Animal StudiesClinical studies show improvements in cognitive scores and activities of daily living in vascular dementia patients.
Limitations: Smaller and less robust evidence base than for stroke or Alzheimer's.
Pediatric Neurodevelopmental
·Animal StudiesStudies in children with neurodevelopmental disorders show improvements in cognitive and behavioral measures.
Limitations: The pediatric evidence base is still developing. Study designs vary.
Safety and Regulatory Status
FDA Status: Not FDA-approved in the United States. Approved in over 60 countries for neurological indications.
Prescription status: Available by prescription in approved countries. Administration requires medical supervision (IV or IM injection). Manufactured by Ever Neuro Pharma (Austria).
Safety context: Administered to thousands of patients in clinical trials and millions in clinical practice globally. The CASTA trial reported adverse event rates comparable to placebo. Not on any FDA list that limits pharmacy preparation.
Generally well-tolerated across multiple RCTs. Common side effects include injection site pain, headache, dizziness, and nausea. Serious adverse events are rare and comparable to placebo.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Cerebrolysin discussion.
Comparison and Related Research
Cerebrolysin is most often compared with other neurotrophic compounds used for cognitive and neuroprotective applications.
Head-to-head comparisons
Full research comparisons covering Cerebrolysin and another peptide side by side.
Cerebrolysin vs Semax
Research comparison of Semax and Cerebrolysin, a synthetic ACTH-derived peptide versus a complex neuropeptide mixture. Mechanisms, evidence levels, administration contexts, and limitations analyzed.
View full comparisonCerebrolysin vs Semax
Research comparison of Cerebrolysin and Semax, a complex porcine-derived neuropeptide mixture versus a synthetic ACTH-derived peptide. Mechanisms, evidence levels, administration contexts, and limitations analyzed.
View full comparisonCerebrolysin vs BPC-157
BPC-157 for tissue repair. Cerebrolysin for neurological recovery. Both Human Trials but targeting different organ systems. Evidence-graded comparison.
View full comparisonCerebrolysin vs Dihexa
Cerebrolysin has decades of clinical use in 40+ countries. Dihexa has dramatic animal data but zero human evidence. The evidence gap is enormous.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The CASTA trial enrolled 1,070 patients with acute ischemic stroke across multiple centers in Asia. Patients received either cerebrolysin or placebo within 12 hours of stroke onset for 10 days. While the primary endpoint (AIDSS composite) did not reach statistical significance in the overall population, post-hoc analyses identified potential benefit in patients with more severe strokes (NIHSS > 12).Heiss WD et al., 2012 in Stroke. View on PubMed
- 2.A multi-center, double-blind trial evaluating three doses of cerebrolysin in patients with mild-to-moderate Alzheimer's disease over 24 weeks. Patients receiving the higher doses showed statistically significant improvements on the ADAS-cog cognitive scale compared to placebo, with the 30 mL dose demonstrating the most consistent benefit across outcome measures.Alvarez XA et al., 2006 in Eur J Neurol. View on PubMed
- 3.A retrospective multi-center cohort study examining cerebrolysin treatment outcomes across different severities of traumatic brain injury. The analysis found that patients with moderate-to-severe TBI who received cerebrolysin showed improved functional recovery scores compared to standard-of-care controls, with the greatest relative benefit observed in the moderate severity group.Muresanu DF et al., 2015 in CNS Neurol Disord Drug Targets. View on PubMed
- 4.This mechanistic study in a rat stroke model demonstrated that cerebrolysin activates the Sonic hedgehog (Shh) signaling pathway, which promotes neurogenesis, oligodendrogenesis, and angiogenesis in the brain after ischemic injury. Blocking the Shh pathway eliminated the neurological benefits, confirming it as a key mediator of cerebrolysin's neurotrophic effects.Zhang L et al., 2013 in Stroke. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.